Perkin-Elmer and PerSeptive merge
This article was originally published in Clinica
Executive Summary
Perkin-Elmer has completed its acquisition of PerSeptive Biosystems in a transaction valued at $360 million in stock. The companies plan to combine resources to develop systems to speed up the process, and reduce the cost of, drug discovery and development.